Search

Cilnidipine

This drug is approved in China, Japan, Korea, India, and several countries in the European Union.[A31970] … Cilnidipine is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995.

Fluasterone

Has antiproliferative effects on HIV-1 and reduces HIV-1 replication.

Dimethylthiambutene

It is now under international control under Schedule I of the UN Single Convention On Narcotic Drugs 1961, presumably due to high abuse potential, although little more information is available. … Dimethylthiambutene (N,N-Dimethyl-1-methyl-3,3-di-2-thienylallylamine, Dimethibutin, Ohton) is an opioid analgesic drug.

Nilotinib

Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). … this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as

NLX-P101

NLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients. … which is overactive in patients with Parkinson’s disease.

CR002

This is a novel therapeutic approach to treat kidney inflammation. … CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation.

Apoptone

Nicergoline

An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.

TRX1

TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. … TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.

Rabeximod

Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.